Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy
Objective The present study evaluated the profile of endoglin (CD105) and vascular endothelial growth factor (VEGF) based on staging and histopathological grading of colorectal cancer as well as their relationship with bevacizumab therapy. Methods A total of 88 cases of colorectal adenoca...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2021-05-01
|
| Series: | Journal of Coloproctology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1724065 |
| _version_ | 1819154167579541504 |
|---|---|
| author | Rahmawati Minhajat Sahyuddin Saleh Tutik Harjianti Andi Fachruddin Benyamin A. M. Luthfi Parewangi Syakib Bakri |
| author_facet | Rahmawati Minhajat Sahyuddin Saleh Tutik Harjianti Andi Fachruddin Benyamin A. M. Luthfi Parewangi Syakib Bakri |
| author_sort | Rahmawati Minhajat |
| collection | DOAJ |
| description | Objective The present study evaluated the profile of endoglin (CD105) and vascular endothelial growth factor (VEGF) based on staging and histopathological grading of colorectal cancer as well as their relationship with bevacizumab therapy.
Methods A total of 88 cases of colorectal adenocarcinoma were included in the present study. The levels of VEGF and CD105 protein were evaluated with enzyme-linked immunosorbent assay (ELISA).
Results There was a significant difference in the level of CD105 (p = 0.002) between metastases and non-metastases subjects, showing that CD105 was higher in metastases subjects (4.59 ng/ml). There was no significant difference in the level of VEGF based on the presence of metastasis (p = 0.625). There was a significant difference in the levels of CD105 (p = 0.038) and VEGF (p = 0.010) between the subjects who received chemotherapy and those who did not. The CD105 level was higher in the subjects who received chemotherapy (4.43 ng/ml); conversely, the level of VEGF was lower in subjects who received chemotherapy (543.65 pg/ml). There was a statistically significant difference in the levels of CD105 (p = 0.003) and VEGF (p = 0.002) between subjects who received bevacizumab therapy and subjects who did not. The levels of CD105 were higher in subjects who received bevacizumab therapy (5.11 ng/ml); in contrast, the level of VEGF was higher in subjects who did not receive bevacizumab therapy (645.92 pg/ml). There was a significant positive correlation between CD105 and VEGF in subjects who did not receive bevacizumab (p < 0.01).
Conclusion The results of this study support a hypothesis of “escape mechanism” in the failure of anti-angiogenesis therapy (anti-VEGF). |
| first_indexed | 2024-12-22T15:16:47Z |
| format | Article |
| id | doaj.art-409c39df4c05466382b38a48b8cbf494 |
| institution | Directory Open Access Journal |
| issn | 2237-9363 2317-6423 |
| language | English |
| last_indexed | 2024-12-22T15:16:47Z |
| publishDate | 2021-05-01 |
| publisher | Thieme Revinter Publicações Ltda. |
| record_format | Article |
| series | Journal of Coloproctology |
| spelling | doaj.art-409c39df4c05466382b38a48b8cbf4942022-12-21T18:21:44ZengThieme Revinter Publicações Ltda.Journal of Coloproctology2237-93632317-64232021-05-01410215616210.1055/s-0041-1724065Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab TherapyRahmawati Minhajat0Sahyuddin Saleh1Tutik Harjianti2Andi Fachruddin Benyamin3A. M. Luthfi Parewangi4Syakib Bakri5Division of Hematology and Medical Oncology, Internal Medicine Department, Faculty of Medicine at Hasanuddin University, Makassar, IndonesiaDivision of Hematology and Medical Oncology, Internal Medicine Department, Faculty of Medicine at Hasanuddin University, Makassar, IndonesiaDivision of Hematology and Medical Oncology, Internal Medicine Department, Faculty of Medicine at Hasanuddin University, Makassar, IndonesiaDivision of Hematology and Medical Oncology, Internal Medicine Department, Faculty of Medicine at Hasanuddin University, Makassar, IndonesiaDivision of Gastroenterology and Hepatology, Internal Medicine Department, Faculty of Medicine at Hasanuddin University, Makassar, IndonesiaDivision of Nephrology and Hypertension, Internal Medicine Department, Faculty of Medicine at Hasanuddin University, Makassar, IndonesiaObjective The present study evaluated the profile of endoglin (CD105) and vascular endothelial growth factor (VEGF) based on staging and histopathological grading of colorectal cancer as well as their relationship with bevacizumab therapy. Methods A total of 88 cases of colorectal adenocarcinoma were included in the present study. The levels of VEGF and CD105 protein were evaluated with enzyme-linked immunosorbent assay (ELISA). Results There was a significant difference in the level of CD105 (p = 0.002) between metastases and non-metastases subjects, showing that CD105 was higher in metastases subjects (4.59 ng/ml). There was no significant difference in the level of VEGF based on the presence of metastasis (p = 0.625). There was a significant difference in the levels of CD105 (p = 0.038) and VEGF (p = 0.010) between the subjects who received chemotherapy and those who did not. The CD105 level was higher in the subjects who received chemotherapy (4.43 ng/ml); conversely, the level of VEGF was lower in subjects who received chemotherapy (543.65 pg/ml). There was a statistically significant difference in the levels of CD105 (p = 0.003) and VEGF (p = 0.002) between subjects who received bevacizumab therapy and subjects who did not. The levels of CD105 were higher in subjects who received bevacizumab therapy (5.11 ng/ml); in contrast, the level of VEGF was higher in subjects who did not receive bevacizumab therapy (645.92 pg/ml). There was a significant positive correlation between CD105 and VEGF in subjects who did not receive bevacizumab (p < 0.01). Conclusion The results of this study support a hypothesis of “escape mechanism” in the failure of anti-angiogenesis therapy (anti-VEGF).http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1724065angiogenesisbevacizumabcolorectal adenocarcinomacd105vegf |
| spellingShingle | Rahmawati Minhajat Sahyuddin Saleh Tutik Harjianti Andi Fachruddin Benyamin A. M. Luthfi Parewangi Syakib Bakri Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy Journal of Coloproctology angiogenesis bevacizumab colorectal adenocarcinoma cd105 vegf |
| title | Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy |
| title_full | Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy |
| title_fullStr | Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy |
| title_full_unstemmed | Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy |
| title_short | Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy |
| title_sort | profiles of endoglin and vascular endothelial growth factor based on staging and histological grading of colorectal cancer and their relationship with bevacizumab therapy |
| topic | angiogenesis bevacizumab colorectal adenocarcinoma cd105 vegf |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1724065 |
| work_keys_str_mv | AT rahmawatiminhajat profilesofendoglinandvascularendothelialgrowthfactorbasedonstagingandhistologicalgradingofcolorectalcancerandtheirrelationshipwithbevacizumabtherapy AT sahyuddinsaleh profilesofendoglinandvascularendothelialgrowthfactorbasedonstagingandhistologicalgradingofcolorectalcancerandtheirrelationshipwithbevacizumabtherapy AT tutikharjianti profilesofendoglinandvascularendothelialgrowthfactorbasedonstagingandhistologicalgradingofcolorectalcancerandtheirrelationshipwithbevacizumabtherapy AT andifachruddinbenyamin profilesofendoglinandvascularendothelialgrowthfactorbasedonstagingandhistologicalgradingofcolorectalcancerandtheirrelationshipwithbevacizumabtherapy AT amluthfiparewangi profilesofendoglinandvascularendothelialgrowthfactorbasedonstagingandhistologicalgradingofcolorectalcancerandtheirrelationshipwithbevacizumabtherapy AT syakibbakri profilesofendoglinandvascularendothelialgrowthfactorbasedonstagingandhistologicalgradingofcolorectalcancerandtheirrelationshipwithbevacizumabtherapy |